Pfizer (PFE), BioNTech (BNTX) Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years

Go back to Pfizer (PFE), BioNTech (BNTX) Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years

Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years

September 20, 2021 6:45 AM EDT

Results are the first from a pivotal trial of any COVID-19 vaccine in children under 12 years of age In participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responses Companies plan to submit these data to the FDA, EMA and other regulatory agencies around the world as soon as possible Results in children under 5 years of age are expected as soon as later this year

NEW YORK AND MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:... More